Prolease-r-hFSH protein (prhFSH) is a recombinant protein of human Follicle-stimulating hormone, which plays an important role in the Endocrine system.
Background of Prolease-r-hFSH
Prolease-r-hFSH protein is a human derived Follicle-stimulating hormone, which is composed of human follicle stimulating hormone protein and subunits. It is a double chain biological drug, widely used in endocrinology, can be used to improve women's fertility, and is widely used in human assisted reproductive technology.
Function of Prolease-r-hFSH
Prolease-r-hFSH has an important impact on the development and function of the female reproductive system. It can stimulate the ovaries to release eggs, promote estrogen secretion in the ovaries, and also promote the development of sperm in the male testes. In the management of female reproductive health, prolease-r-hFSH can be used to stimulate follicular development and ovulation, and increase the chances of conception.
Prolease-r-hFSH related signaling pathways
The signaling pathways related to prolease-r-hFSH protein can enhance luteinization and fertility in the ovary, while also contributing to successful fertilization of the egg. Follicle-stimulating hormone (FSH) is an important regulator, which can help maintain reproductive health and fertility. Prolease-r-hFSH protein can stimulate the growth and differentiation of Germ cell in ovary and testis through FSH receptor.
The PRH mediated signaling pathways mainly include cAMP-PKA and ERK1/2. FSH binds to its surface receptors, which will lead to changes in receptor structure, thereby initiating intracellular signal transduction pathways. This pathway includes both PKA dependent pathways and ERK1/2 signaling pathways. The PKA dependent signaling pathway leads to the generation of cAMP, leading to increased ovarian growth and follicular development. The activation of ERK1/2 pathway can inhibit the synthesis of Prostaglandin, thus contributing to better maintaining ovarian function and preventing abortion.
Prolease-r-hFSH related diseases
Prolease-r-hFSH protein is related to Female infertility, ovarian insufficiency, Polycystic ovary syndrome and other diseases. In clinical practice, prolease-r-hFSH protein can be used to stimulate the development and ovulation of ovarian follicles, as well as for the development of male sperm.
PRH is also closely related to the onset of diseases. For example, excessive stimulation (OHSS) is a complication related to PRH, which is caused by excessive use of drugs that stimulate the ovaries and increase vascular permeability, leading to excessive fluid accumulation in the abdominal and thoracic cavities. Approximately 0.1% -2% of infertile women experience OHSS. In addition, PRH may also play a promoting role in certain malignant tumors. For example, for certain ovarian cancer cells, the role of PRH is believed to play in tumor cell proliferation and survival, and PRH may be involved in regulating the proliferation and apoptosis pathways of ovarian cancer cells.
Potential applications in medicine of prolease-r-hFSH
Prolease-r-hFSH protein has a wide range of applications in medicine. First, it is widely used in assisted reproductive technology, such as external fertilization and ovarian stimulation. Secondly, the prolease-r-hFSH protein can also be used to promote the development of sperm in male testes. Finally, prolease-r-hFSH protein can be used to treat infertility caused by low follicle-stimulating hormone.
Related investigational drugs
PRH related drugs under development, including Cetrorelix, Elagolix, and Abarelix. Cetrorelix is a non-peptide GnRH antagonist that can be used for controlling endogenous ovarian stimulation sequences (COH) to increase the chances of IVF success. Elagolix is an oral highly selective GnRH receptor antagonist, which can be used to treat acute and Chronic pain. Abarelix is an antagonist targeting the LHRH receptor and can be used to treat progressive diseases of prostate cancer.
Currently, there are various investigational drugs related to the prolease-r-hFSH protein, some of which are in the clinical trial stage. For example, PK-14105 is a recombinant human receptor FSH ligand dedicated to improving the therapeutic efficacy of infertility patients. AZD-4901 is an oral FSH inhibitor that is expected to provide a more convenient method for treating infertility.
